In contrast to etoposide’s triggering of caspase-3 activation, CLL cells treated with NGAL or IFN-γ displayed lower levels of active caspase-3 than untreated cells (Figure 6B). This evidence concerns the gene LCN2 and B-cell chronic lymphocytic leukemia.